

Organized by:



In collaboration with:



Under the auspices of:



# IMMUNOTHERAPY bridge 2023

Naples (Italy)

November 29<sup>th</sup> - 30<sup>th</sup>, 2023

Aula Magna - Università degli Studi di Napoli Federico II  
Via Partenope 36, Napoli

# 2023

# GENERAL INFORMATION

---



## CME PROVIDER AND ORGANIZING SECRETARIAT:

3P Solution Srl

Corso Magenta 81, 20123 Milan

Phone +39 02 36631574

[www.3psolution.it](http://www.3psolution.it)

[info@3psolution.it](mailto:info@3psolution.it)

[info@melanomabridge.org](mailto:info@melanomabridge.org)

## OFFICIAL LANGUAGE:

The official language is English

## REGISTRATION:

Only registered attendees will be admitted to the meeting.


The registration fee includes:

- participation in the scientific sessions
- congress kit (badge, notepad, pen)
- coffee breaks and lunches from Nov 29<sup>th</sup> to Nov 30<sup>th</sup>

# GENERAL INFORMATION

## CONGRESS VENUE:

Aula Magna - Università degli Studi di Napoli Federico II  
Via Partenope 36, Napoli  
80121 - Naples



AIRPORT

RAILWAY  
STATION

CONGRESS  
VENUE

# SCIENTIFIC RATIONAL

---

Over the last years, an extensive research has improved our understanding of tumor immunology and enabled the development of novel treatments that can harness the patient's immune system and prevent immune escape.

Through numerous clinical trials and real-world experience, a large amount of evidence of the potential for long-term survival with immunotherapy agents has been accumulated in various types of malignancy, starting from melanoma to extend to other tumors.

The results of these studies have also highlighted a number of recurring observations with immuno-oncology agents, including their potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The clinical success of immune checkpoint blockade with anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and anti-programmed death (PD)-1/PD-ligand (L1) inhibitor in melanoma and other cancers has encouraged increasing development of other immunotherapies, particularly monoclonal antibodies with other immune targets, adoptive cell transfer and vaccines. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Study results have highlighted a number of recurring observations, including the immunotherapy potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The successes of the immune-oncology is strongly correlated with the immune system ability of "memory" and adaptability, to improve the time of survival and without selecting resistant form of tumoral cells. Another advantage is that the efficacy of immunotherapy drugs does not seem to be particularly influenced by histology and mutations.

First session of the congress will be jointly organized with the Society for ImmunoTherapy of Cancer (SITC).

Hence, the state of the art of immunotherapy from the clinical point of view in various types of malignancies will be exhaustively discussed and on targeting cancer through stimulation of innate immunity with intratumorals.

Then the "Great Debate" sessions, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed from different points of view.

Conclusions will be drawn after the last session on Neo-Adjuvant therapies in different types of cancer.

# SCIENTIFIC PROGRAM

Wednesday, Nov 29<sup>th</sup>, 2023



09:40 am	Welcome Coffee and Registration**
09:55 am	Introduction and objectives <b>Paolo A. Ascierto</b>
	<b>SITC SESSION CELL THERAPIES</b> <i>Chairpersons: Leisha A. Emens, Sofie Wilgenhof</i>
10:00 am	CAR-T <b>Marcela Maus</b>
10:15 am	Q&A
10:20 am	Novel CD4 T cell-based therapies <b>Chrystal Paulos</b>
10:35 am	Q&A
10:40 am	Harnessing B cells for novel immunotherapies: where are we headed? <b>Tullia Bruno</b>
10:55 am	Q&A
11:00 am	Myeloid-induced immune deviation in pancreatic cancer <b>Vincenzo Bronte</b>
11:15 am	Q&A
11:20 am	CARs and armored CARs: moving cellular therapy forward <b>Renier Brentjens</b>
11:35 am	Q&A
11:40 am	Best of SITC 2023 for clinical development and trials <b>Paolo A. Ascierto</b>
11:55 am	Q&A
12:00 pm	<b>LECTURE - How immunotherapy changed the treatment story for endometrial and cervical cancer</b> <b>Michele Bartoletti</b>
12:30 pm	<b>SYMPOSIUM – New evidences in immunotherapy</b> <i>Chairperson: Paolo A. Ascierto</i> - IO in metastatic non oncogene addicted NSCLC disease: consolidated options to cover the unmet need, <b>Alessandro Morabito</b> - IO combinations in aRCC: new achievements and challenges, <b>Roberto Iacovelli</b> - Immunotherapy in GI cancer: current treatment landscape and challenges, <b>Antonio Avallone</b>

\*Speakers invited

\*\*Not included in CME accredited program

# SCIENTIFIC PROGRAM

Wednesday, Nov 29<sup>th</sup>, 2023



01:20 pm	Lunch**
	<b>SESSION 2</b> <b>TRENDS AND BIOMARKERS IN IMMUNOTHERAPY</b> <i>Chairpersons: Luigi Buonaguro, Alfredo Budillon</i>
02:15 pm	Head and Neck Cancer: neoadjuvant trial design to develop novel therapies and biomarkers of response <b>Robert L. Ferris</b>
02:30 pm	Q&A
02:35 pm	Engage, Expand, Enable: Combination IO strategy for cold tumors <b>James L. Gulley</b>
02:50 pm	Q&A
02:55 pm	Novel biomarkers of ICI in metastatic melanoma <b>Tomas Kirchhoff</b>
03:10 pm	Q&A
03:15 pm	Novel insights into the mechanisms of radiation-induced anti-tumor immunity <b>Sandra Demaria</b>
03:30 pm	Q&A
03:35 pm	Teaching lymphoma patients to target their tumor antigens and to prevent antigen escape <b>Joshua Brody</b>
03:50 pm	Q&A
03:55 pm	Non melanoma skin cancers <b>Paolo A. Ascierto</b>
04:10 pm	Q&A
04:15 pm	Spatial omics in immunotherapy trials: unpacking the challenges <b>Carlo Bifulco</b>
04:30 pm	Q&A
04:35 pm	Updates on Radiation and Immunotherapy <b>Silvia Formenti</b>
04:50 pm	Q&A
04:55 pm	Coffee break**

\*Speakers invited

\*\*Not included in CME accredited program

# SCIENTIFIC PROGRAM

Wednesday, Nov 29<sup>th</sup>, 2023



## **GREAT DEBATE SESSION**

*Chairpersons:* **Paolo A. Ascierto, Leisha A. Emens, Igor Puzanov**

05:10 pm Are MDSC important in affecting cancer progression?  
**Pawel Kalinski VS Brahm Segal**

05:40 pm Discussion

05:50 pm Cancer vaccines Vs Adoptive Cell therapy  
**Pawel Kalinski VS Allison Betof Warner**

06:20 pm Discussion

06:30 pm Bispecific VS combination therapy  
**James L. Gulley VS Akash Patnaik**

07:00 pm Discussion

# 2023

*\*Speakers invited*

*\*\*Not included in CME accredited program*

# SCIENTIFIC PROGRAM

Thursday, Nov 30<sup>th</sup>, 2023



## SESSION 3 ORGAN SPECIFIC IMMUNE RESPONSE

*Chairpersons:* Omid Hamid, Paul Nathan

- 09:15 am Surviving in the Lymphoma Microenvironment: a tough challenge for CAR T cells  
**Marco Ruella**
- 09:30 am Efforts to achieve immune mediated tumor eradication in the CNS  
**Bart Neyns**
- 09:45 am Activating Innate Immunity in Prostate Cancer: From Bedside-to-Bench and Back  
**Akash Patnaik**
- 10:00 am Immunotherapy for hepatocellular carcinoma: current status and future perspectives  
**Piera Federico**
- 10:15 am Innovating immunotherapy for gastrointestinal cancers  
**Gregory B. Lesinski**
- 10:30 am What's new in Immunotherapy: Lung and Mesothelioma  
**Alessandro Morabito**
- 10:45 am Emerging Predictive Immune Biomarkers in Breast Cancer  
**Leisha A. Emens**
- 11:00 am New Developments in Immunotherapy for Ovarian Cancer  
**Kunle Odunsi**
- 11:15 am Discussion
- 11:30 am *Coffee break\*\**

## GREAT DEBATE SESSION

*Chairpersons:* Paolo A. Ascierto, Leisha A. Emens, Igor Puzanov

- 11:40 am Neo-antigens VS alternative antigens  
**Stephen Schoenberger VS Cristina Puig-Saus**
- 12:10 pm Discussion
- 12:20 pm Immunoscore VS Genes signature  
**Jerome Galon VS Christian Blank**
- 12:50 pm Discussion
- 01:00 pm TCR engagers VS CAR-T  
**Rom Leidner VS Renier Brentjens**
- 01:30 pm Discussion

*\*Speakers invited*

*\*\*Not included in CME accredited program*



# SCIENTIFIC PROGRAM

Thursday, Nov 30<sup>th</sup>, 2023



01:40 pm Lunch\*\*

## SESSION 4

### NEOADJUVANT IMMUNOTHERAPY

Chairpersons: **Paolo A. Ascierto, Elizabeth Burton**

02:40 pm Fine-Tuning Neoadjuvant Immunotherapy for Triple Negative Breast Cancer  
**Leisha A. Emens**

02:55 pm Advances in Neoadjuvant and Perioperative Immunotherapy for Resectable Non-small Cell Lung Cancer  
**Tina Cascone**

03:10 pm Harnessing the power of neoadjuvant immunotherapy for colorectal cancer  
**Myriam Chalabi**

03:25 pm Skin Cancers:  
Melanoma, **Georgina Long**  
Non melanoma skin cancer, **Neil Gross**

03:55 pm Multiplex immunofluorescence assays for predicting response to anti-PD-1-based therapies  
**Janis Taube**

04:10 pm Validation of a pan-tumor scoring system of pathologic response to neoadjuvant immunotherapy: update on SITC effort  
**Julie Stein Deutsch**

04:25 pm Discussion

04:50 pm Conclusions  
**Paolo A. Ascierto, Leisha A. Emens, Igor Puzanov**

2023

\*Speakers invited

\*\*Not included in CME accredited program

# PRESIDENCY



## **Paolo A. Ascierto**

Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute IRCCS "Fondazione G. Pascale", Naples, Italy



## **Leisha A. Emens**

Professor of Medicine, Director of Translational Immunotherapy for the Women's Cancer Research Center, Co-Leader, Hillman Cancer Immunology/Immunotherapy Program, UPMC Hillman Cancer Center/Magee Women's Hospital, Pittsburgh, PA, US



## **Bernard A. Fox**

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center – Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, US



## **Igor Puzanov**

Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

# SCIENTIFIC BOARD

## **Sanjiv S. Agarwala**

Professor of Hematology & Oncology, Temple University School of Medicine, Philadelphia, PA, US

## **Paolo A. Ascierto**

Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute IRCCS "Fondazione G. Pascale", Naples, Italy

## **Carlo Bifulco**

Chief Medical Officer, Providence Genomics, Director of Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

## **Elizabeth M. Burton**

Executive Director, Translational Research Initiative Development, Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, US

## **Lisa H. Butterfield**

Adjunct Professor, Microbiology and Immunology, University of California San Francisco; Vice President, PICI Research Center/ PICI Research & Development, San Francisco, CA, US

## **Corrado Caracò**

Director of Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy

## **Mary Dean**

Executive Director, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

## **Sandra Demaria**

Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology, Weill Cornell Medical College, New York, NY, US

# SCIENTIFIC BOARD

---

**Reinhard Dummer**

Vice Director, Department of Dermatology; Director, Clinical Trials Comprehensive Cancer Center Zurich (CCCZ), University Hospital Zurich, Zurich, Switzerland

**Alexander M.M. Eggermont**

Chief Scientific Officer, Board of Directors, Princess Máxima Center; Professor of Clinical&Translational Immunotherapy, Utrecht University, Utrecht, The Netherlands

**Leisha A. Emens**

Professor of Medicine, Director of Translational Immunotherapy for the Women's Cancer Research Center, Co-Leader, Hillman Cancer Immunology/Immunotherapy Program, UPMC Hillman Cancer Center/Magee Women's Hospital, Pittsburgh, PA, US

**Bernard A. Fox**

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center – Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

**Jerome Galon**

Research Director, National Institute of Health and Medical Research (INSERM), Director, Integrative Cancer Immunology Team, Cordeliers Research Center, Paris, France

**Claus Garbe**

Professor of Dermatology, President of the European Association of DermatoOncology (EADO), Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany

**Jeffrey E. Gershenwald**

Dr. John M. Skibber Endowed Professor of Surgery, Department of Surgical Oncology, Medical Director, Melanoma and Skin Center, The University of Texas, MD Anderson Cancer Center, Distinguished Senior Lecturer, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA

**Omid Hamid**

Chief of Research/ Immuno-Oncology, Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, US

**Giuseppe Masucci**

Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

**Olivier Michielin**

Full Professor, Chair of Oncology Department and Precision Oncology Service, Geneva University Hospital, Geneva; Co-Director of the Swiss Cancer Center Léman, Agora - Lausanne, Switzerland

**Iman Osman**

Professor, Departments of Medicine (Oncology) and Urology, Director, Interdisciplinary Melanoma Program, Associate Dean for Translational Research Support, NYU Grossman School of Medicine, New York, NY, US

**Giuseppe Palmieri**

Full Professor of Medical Oncology, University of Sassari; Immuno-Oncology & Targeted Cancer Biotherapies, Sassari University Hospital; Associate Researcher, Head of Unit of Cancer Genetics, National Research Council (CNR); Head, Institute of Genetic & Biomedical Research (IRGB), Sassari, Italy

**Michael A. Postow**

Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US

**Igor Puzanov**

Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

**Magdalena Thurin**

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, US

**Tara Withington**

Executive Director Emeritus, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

# FACULTY

---

**Paolo A. Ascierto**

Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy

**Antonio Avallone**

Unit of Abdominal Medical Oncology, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

**Michele Bartoletti**

Medical Oncologist, Department of Clinical Oncology, OMP - IRCCS CRO Aviano National Cancer Institute, Aviano, Italy

**Allison Betof Warner**

Assistant Professor of Medicine (Oncology), Director, Melanoma Medical Oncology Program, Director, Solid Tumor Cellular Therapy Leader, Melanoma & Cutaneous Oncology Clinical Research Group, Stanford University School of Medicine, Stanford Cancer Center, Stanford, CA, US

**Carlo Bifulco**

Chief Medical Officer, Providence Genomics, Director of Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

**Christian Blank**

Medical Oncology and Research Group Leader Tumor Immunology, Netherlands Cancer Institute, Amsterdam; Medical Oncology

**Renier Brentjens**

Deputy Director & Chair, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

**Joshua Brody**

Director, Lymphoma Immunotherapy Program, Hess Center for Science and Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, US

**Vincenzo Bronte**

Scientific Director of the IRCCS Istituto Oncologico Veneto (IOV), Padua, Italy

**Tullia Bruno**

Assistant Professor Researcher, UPMC Hillman Cancer Center, Pittsburgh, PA, US

**Alfredo Budillon**

Scientific Director, National Cancer Institute, IRCCS Fondazione "G. Pascale", Naples, Italy

**Luigi Buonaguro**

Director Innovative Immunological Models Unit, National Cancer Institute, IRCCS Fondazione "G. Pascale", Naples, Italy

**Elizabeth M. Burton**

Executive Director, Translational Research Initiative Development, Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Tina Cascone**

Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Myriam Chalabi**

Medical Oncologist, GI cancers, Netherlands Cancer Institute, Amsterdam, The Netherlands

**Sandra Demaria**

Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology, Weill Cornell Medical College, New York, NY, US

**Leisha A. Emens**

Professor of Medicine, Director of Translational Immunotherapy for the Women's Cancer Research Center, Co-Leader, Hillman Cancer Immunology/Immunotherapy Program, UPMC Hillman Cancer Center/Magee Women's Hospital, Pittsburgh, PA, US

**Julie Stein Deutsch**

Assistant Professor of Dermatology and Pathology, Division of Dermatopathology, Dept. of Dermatology Johns Hopkins University, Baltimore, MD, US

**Piera Federico**

Medical Executive at the Oncology Division, "Ospedale del Mare" Hospital, Naples, Italy

# FACULTY

---

**Robert L. Ferris**

Director, UPMC Hillman Cancer Center, Professor of Oncology, Associate Vice Chancellor for Cancer Research Center, Professor of Otolaryngology, of Immunology and of Radiation Oncology, University Pittsburgh School of Medicine, PA, US

**Silvia Chiara Formenti**

Chairman of the Department of Radiation Oncology, Weill Cornell Medicine; Associate Director of the Meyer Cancer Center, Radiation Oncologist in Chief, New York-Presbyterian Hospital, New York, NY, US

**Jerome Galon**

Research Director, National Institute of Health and Medical Research (INSERM), Director, Integrative Cancer Immunology Team, Cordeliers Research Center, Paris, France

**Neil D. Gross**

Professor, Department of Head and Neck Surgery, Division of Surgery Section Chief, Oropharynx Cancer, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**James Gulley**

Co-Director, Center for Immuno-Oncology, Center for Cancer Research and Clinical Director, National Cancer Institute, National Institutes of Health, Bethesda, MD, US

**Omid Hamid**

Chief of Research/ Immuno-Oncology, Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, US

**Roberto Iacovelli**

Associate Professor, Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

**Pawel Kalinski**

SVP, Team Science; Chair, Department of Immunology; Professor of Oncology & Chief, Translational Immuno-Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, US

**Tomas Kirchhoff**

Associate Professor, Department of Population Health, Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, US

**Rom Leidner**

Co-Medical Director Head & Neck Cancer, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, US

**Gregory B. Lesinski**

Professor, Vice Chair for Basic Research, Department of Hematology & Medical Oncology, Associate Director for Basic Research, Co-Director, Translational GI Malignancy Program, Winship Cancer Institute of Emory University, Atlanta, GA, US

**Georgina Long**

Co-medical Director , Chair of Melanoma Medical Oncology and Translational Research presso MIA e Royal North Shore Hospital, Melanoma Institute Australia, The University of Sydney, Wollstonecraft NSW, Australia

**Marcela V. Maus**

Associate Professor of Medicine, Harvard Medical School; Director of Cellular Immunotherapy, Cancer Center, Massachusetts General Hospital, Boston, MA, US

**Alessandro Morabito**

Director of Thoracic Medical Oncology, National Cancer Institute, IRRCS "Fondazione G. Pascale", Naples, Italy

**Paul Nathan**

Consultant Medical Oncologist, Mount Vernon Cancer Centre Honorary Professor of Oncology UCL Honorary Consultant Medical Oncologist UCLH, Mount Vernon Cancer Centre UCL, University College Of London, London, UK

**Bart Neyns**

Head of Department Medical Oncology, Universitair Ziekenhuis (UZ) Brussel; Clinical Professor at the Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Brussels, Belgium

**Kunle Odunsi**

Director, University of Chicago Medicine Comprehensive Cancer Center; Dean for Oncology, Biological Sciences Division, The University of Chicago, Chicago, IL, US

# FACULTY

---

**Akash Patnaik**

Associate Professor; Director, Laboratory for Developmental Therapeutics; Attending Physician, The University of Chicago, Chicago, IL, US

**Chrystal M. Paulos**

Associate Professor, Department of Surgery / Microbiology & Immunology, Director of Translational Research, Cutaneous Malignancies, Winship Cancer Institute at Emory University Atlanta, GA, US

**Cristina Puig-Saus**

Assistant Professor, University of California, Los Angeles (UCLA), Los Angeles, CA, US

**Igor Puzanov**

Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

**Marco Ruella**

Assistant Professor of Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, US

**Stephen Schoenberger**

Professor, La Jolla Institute for Immunology, Adjunct Prof. UCSD Moores Cancer Center, Director of Translational Science, San Diego Center for Precision Immunotherapy, La Jolla Institute for Immunology, San Diego, CA, USA

**Brahm Segal**

Chair, Department of Internal Medicine, Chief, Division of Infectious Diseases, Professor of Oncology, Member, Department of Immunology, Roswell Park Comprehensive Cancer Center; Professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, US

**Janis Taube**

Director, Division of Dermatopathology, Professor of Dermatology, Johns Hopkins University, School of Medicine, Baltimore, MD, US

**Sofie Wilgenhof**

Medical oncologist and IO specialist, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

---

## CONTINUING MEDICAL EDUCATION

3P Solution has been accredited by the Ministry of Health as a CME Standard Provider (code 327, authorized on October 15th, 2012).

3P Solution owns the responsibility for the content, quality, and ethical correctness of this CME activity.

Immunotherapy Bridge Congress has been accredited (ID CME 327-396014) with 4,2 CME credits with a formative technical-professional objective "Technical professional content (knowledge and competences) specifications of each profession, of all specialization and ultraspecialist activity. Rare disease and Gender medicine", belonging to formative technical professional objective area, for 201 participants of the following professions: medical doctors, pharmacists, biologists, nurses, pediatric nurses.

The number of attendees can not exceed the number of accredited participants. If the number of participants is exceeded, attendees will be admitted to the scientific sessions on the basis of registration order.

In order to receive credits, participants must:

1. Attend at least 90% of the accredited CME sessions (attendance check: required sign at the beginning and at the end of works each day)
2. Complete the evaluation form at the end of the Congress.

CME certificate will be sent at the end of the validation procedure.

## MY ECM

Age.na.s activated MyEcm service (personalized page available to any health professional), which enables you to:

1. Consult the CME events offer;
2. Refer to the summary of events attended and earned credits;
3. Provide an assessment of courses organized by the Provider.

To access online services please log on to <http://ape.agenas.it/professionisti/myecm>.

If this meeting fulfilled your expectations, please click on  and give your assessment.

Immunotherapy Bridge is sponsored by an unrestricted grant from:

---

**GOLD SPONSOR**



**SILVER SPONSOR**



**SPONSOR**

